Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 50 • 2019 ACR/ARP Annual Meeting
Circulating 25(OH)D, LL-37 and Antimicrobial Protein and Peptide (APP) Levels Are Altered Prior to Onset of Rheumatoid Arthritis
Vidyanand Anaparti¹, Xiaobo Meng ¹, Hemshekhar Mahadevappa ¹, Irene Smolik ¹, Neeloffer Mookherjee ¹ and Hani El-Gabalawy ¹, ¹University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Epidemiological studies suggest vitamin D deficiency as a potential risk factor for rheumatoid arthritis (RA) development, a chronic autoimmune disorder highly prevalent in indigenous…
Abstract Number: 183 • 2019 ACR/ARP Annual Meeting
Exploring Heterogeneity in Rheumatoid Arthritis: Patient Profiling Through Principal Component and Cluster Analysis of the BRASS Registry
Jeffrey Curtis¹, Michael Weinblatt ², Kenneth Saag ¹, Vivian Bykerk ³, Christina Charles-Schoeman ⁴, Stefano Fiore ⁵, Gregory St John ⁶, Toshio Kimura ⁷, Shen Zheng ⁵, Clifton Bingham ⁸, Grace Wright ⁹, Martin Bergman ¹⁰, Kamala Nola ¹¹, Daniel Furst ⁴ and Nancy Shadick ², ¹University of Alabama at Birmingham, Birmingham, AL, ²Brigham and Women's Hospital, Boston, MA, ³Hospital for Special Surgery, New York City, NY, ⁴University of California, Los Angeles, CA, ⁵Sanofi Genzyme, Bridgewater, NJ, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁸Johns Hopkins University, Baltimore, MD, ⁹Private Practice, New York City, NY, ¹⁰Drexel University College of Medicine, Stockholm, Sweden, ¹¹Lipscomb University College of Pharmacy & Health Sciences, Nashville, TN
Background/Purpose: Data-driven principal component (PC) and cluster analysis has the potential to identify previously unknown patient subgroups within a rheumatoid arthritis (RA) registry to establish…
Abstract Number: 258 • 2019 ACR/ARP Annual Meeting
Health Services Utilization as Recommended by the American Diabetes Association Among Middle-Aged Patients Disabled with Rheumatoid Arthritis and Diabetes Mellitus
Geyanne Lui¹, Mangala Rajan ¹, Lisa Kern ¹, Laura Pinheiro ¹, Monika Safford ¹, Jeffrey Curtis ² and Iris Navarro-Millan ¹, ¹Weill Cornell Medicine, New York, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Medicare beneficiaries who are disabled (coverage by the Social Security Disability Insurance (SSDI)) with rheumatoid arthritis (RA) and diabetes mellitus (DM) and under 65…
Abstract Number: 441 • 2019 ACR/ARP Annual Meeting
Multidimensional Health Assessment Questionnaire (MDHAQ) Scores in Spain vs USA: Similar Scores for Clinical Status and Self-report of Depression in Rheumatoid Arthritis (RA) but Poorer Scores for Both in Spondyloarthropathies (SpA) in Spain
Rosa Morlà¹, R. Castellanos ², Virginia Ruiz-Esquide ³, Julio Ramirez ⁴, Raimon Sanmarti ⁵, Jose Gomez-Puerta ⁵, Mariam Riad ⁶, Isabel Castrejon ⁶ and Theodore Pincus ⁶, ¹Rheumatology Unit, Xarxa Sanitaria Santa Tecla, Tarragona. Rheumatology, Fundacio Clinic, Barcelona, Barcelona, Spain, ²Fundacio Clinic. Hospital Clinic de Barcelona, Barcelona, Spain, ³Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ⁴Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ⁵Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁶Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Associations of depression with clinical status in RA1 and differences in clinical status in different countries2 have been reported. We compared MDHAQ (multidimensional health…
Abstract Number: 466 • 2019 ACR/ARP Annual Meeting
Predicting Risk of Radiographic Progression for Patients with Rheumatoid Arthritis
Thomas Huizinga ¹, Michael Weinblatt ², Nancy Shadick ², Cecilie Heegaard Brahe ³, Mikkel Østergaard ⁴, Merete Lund Hetland ⁵, Karen Hambardzumyan ⁶, Saedis Saevarsdottir ⁶, Megan Horton ⁷, Brent Mabey ⁸, Darl Flake ⁸, Alexander Gutin ⁸, Rotem Ben-Shachar ⁷, Eric Sasso ⁹ and Jeffrey Curtis¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²Brigham and Women's Hospital, Boston, MA, ³EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark, ⁴Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ⁵DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷Myriad Genetics, Inc., Salt Lake City, UT, ⁸Myriad Genetics, Inc, South San Francisco, CA, ⁹Crescendo Bioscience, South San Francisco, CA, ¹⁰University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The multi-biomarker disease activity (MBDA) blood test has been shown to be a predictor of risk for radiographic progression in patients with rheumatoid arthritis…
Abstract Number: 503 • 2019 ACR/ARP Annual Meeting
A Pilot Phase 1, Randomized, Double-blind, Two-arm, Parallel Group, Single-dose Study to Evaluate the Safety and Pharmacokinetics of CT-P17 and Humira in Healthy Male Subjects
Edward Keystone¹, Daniel Furst ², Malcolm Boyce ³, Frans van den Berg ³, SangJoon Lee ⁴, SungHyun Kim ⁴, YunJu Bae ⁴, GoEun Yang ⁴, JuHeon Koo ⁴, EunJin Choi ⁴ and Jonathan Kay ⁵, ¹Mount Sinai Hospital, Toronto, Canada, ²University of California, Los Angeles, CA, ³Hammersmith Medicines Research, London, United Kingdom, ⁴Celltrion Inc., Incheon, Republic of Korea, ⁵UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA
Background/Purpose: CT-P17 is a recombinant humanized monoclonal antibody that was developed as a biosimilar to the reference product, adalimumab. This was a first in human…
Abstract Number: 552 • 2019 ACR/ARP Annual Meeting
In the Real World Clinical Setting Etanercept Biosimilar SB4(BENEPAIL®) Demonstrates Equivalent Safety and Effectiveness in Biological Naïve as Well as with ENBREL® Pretreated RA,SPA, and PSA Patients
Herbert Kellner¹, ¹Praxis Prof. Herbert Kellner, Munich, Germany
Background/Purpose: Background: Biosimilar TNFα inhibitors have only become available in the last few years. Etanercept bisosimilar SB-4 Benepali® has been launched in March 2016 in…
Abstract Number: 921 • 2019 ACR/ARP Annual Meeting
Indicators of Actionable Levels of Atherosclerosis in RA Patients Who Appear to Have Low or Intermediate Atherosclerotic Cardiovascular Risk Based on Standard Risk Algorithms
Jon Giles¹, Cecilia Chung ², Mary Chester Wasko ³, Amy Kao ³, Annette Oeser ², C. Michael Stein ² and Joan Bathon ⁴, ¹Columbia University, Vagelos College of Physicians & Surgeons, New York, NY, ²Vanderbilt University, Nashville, TN, ³Allegheny Health Network-West Penn Hospital, Pittsburgh, PA, ⁴Division of Rheumatology, Columbia University, New York, NY
Background/Purpose: In the general population, statins reduces atherosclerotic cardiovascular disease (ASCVD) events in those with a computed tomography (CT)-assessed coronary artery calcium (CAC) score ≥100…
Abstract Number: 1081 • 2019 ACR/ARP Annual Meeting
Characteristics of Patients with Seropositive or Seronegative Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from the US-Based Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries
Alexis Ogdie¹, Mei Liu ², Sabrina Rebello ², Angel Cronin ², Blessing Dube ², Robert McLean ², Esther Yi ³, Peter Hur ³ and Philip Mease ⁴, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) share many clinical features but are differentiated by key clinical and molecular characteristics. Patients…
Abstract Number: 1328 • 2019 ACR/ARP Annual Meeting
The Patient’s Perspective on a Disease Flare During Tapering of DMARDs in Rheumatoid Arthritis
Elise van Mulligen¹, Angelique Weel ², Martijn Kuijper ², Mieke Hazes* ³, Annette van der Helm-van Mil ⁴ and Pascal de Jong ¹, ¹Erasmus MC, Rotterdam, Netherlands, ²Maasstad Hospital, Rotterdam, Netherlands, ³Erasmus MC, University Medical Center Rotterdam, Department of Rheumatology, Rotterdam, The Netherlands, Rotterdam, Netherlands, ⁴LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: Previous studies have shown that it is possible to taper DMARDs in RA patients with an inactive disease, but this is accompanied with a…
Abstract Number: 1355 • 2019 ACR/ARP Annual Meeting
A Comparison of Clinical Improvement Following a Major Therapeutic Change Utilizing Updated Treatment Thresholds Defined by Three Different Disease Activity Measures
Grant Cannon¹, Wei Chen ¹, JIncheng Shen ², Neil Accortt ³, David Collier ⁴ and Brian Sauer ¹, ¹Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, ²Univeristy of Utah, Salt Lake City, UT, ³Amgen, Thousand Oaks, CA, ⁴Amgen Inc., Thousand Oaks, CA
Background/Purpose: Despite ACR recommendations to initiate a major therapeutic change (MTC) in rheumatoid arthritis (RA) patients with moderate/severe disease activity, our recent work has shown…
Abstract Number: 1380 • 2019 ACR/ARP Annual Meeting
Patient Characteristics, Treatment Patterns, and Treatment Persistency in Biologic DMARD-Experienced Rheumatoid Arthritis Patients in a US RA Registry
Robin Dore¹, Jenya Antonova ², Leslie Harrold ³, Lawrence Chang ², Emily Scherer ⁴, Angel Cronin ⁵, Kelechi Emeanuru ⁵ and Joel Kremer ⁶, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³Corrona, LLC and University of Massachusetts Medical School, Worcester, MA, ⁴Corrona, LLC, Cambridge, MA, ⁵Corrona, LLC, Waltham, MA, ⁶Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Multiple treatment options are available for patients with RA. ACR guidelines recommend initiating treatment with a conventional synthetic DMARD (csDMARD). If a patient fails…
Abstract Number: 1416 • 2019 ACR/ARP Annual Meeting
B Cell Profile for Early Identification of Optimal Responders to TNF-inhibitors in Rheumatoid Arthritis
Cristina Sobrino¹, Borja Hernández-Breijo ², Carlota García-Hoz ³, Israel Nieto-Gañán ⁴, Victoria Navarro-Compán ⁵, Ana Martínez-Feito ⁶, javier Bachiller ¹, Gema Bonilla ⁷, Cristina Pijoán-Moratalla ¹, Paloma Lapuente-Suanzes ⁸, Dora Pascual-Salcedo ², Alejandro Balsa ⁷, Garbiñe Roy ⁴, Mónica Vázquez Díaz ¹, Luisa María Villar ⁴, Chamaida Plasencia ⁷ and Eulalia Rodríguez-Martín ⁴, ¹Rheumatology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, ²Immuno-Rheumatology Research Group, IdiPAZ. La Paz University Hospital, Madrid, Spain, ³Immunology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, ⁴Immunology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, ⁵University Hospital La Paz, IdiPaz, Madrid, Spain, ⁶Immuno-Rheumatology Research Group, IdiPAZ & Immunology Department. La Paz University Hospital, MADRID, Spain, ⁷Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain, ⁸University Hospital Ramón y Cajal, Madrid
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory and heterogeneous autoimmune disorder of unknown etiology characterized by progressive joint damage. Although TNF inhibitors (TNFi) have…
Abstract Number: 1773 • 2019 ACR/ARP Annual Meeting
The Card9-Neutrophil Signaling Axis Is Critical to Induction of Th17-Mediated Arthritis in SKG Mice
Ruth Napier¹, Ellen Lee ¹, Emily Vance ¹, Beatitude Steffen ², Shimon Sakaguchi ³ and Holly Rosenzweig ⁴, ¹Oregon Health & Science University and Portland VA Hospital, Portland, OR, ²Oregon Health & Science University and Portland VA Hospital, Portland, ³Osaka University, Osaka, Japan, ⁴Oregon Health & Science University and Portland VA Hospital, Oregon
Background/Purpose: Caspase recruitment domain-containing protein 9 (CARD9) is an adaptor protein downstream of C-type lectin receptor signaling within myeloid cells. CARD9 is critical for anti-fungal immunity;…
Abstract Number: 1895 • 2019 ACR/ARP Annual Meeting
Biologics Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Non-calcified Coronary Plaque Progression and Stabilizing Vulnerable Plaques
George Karpouzas¹, Sarah Ormseth ¹, Elizabeth Hernandez ² and Matthew Budoff ¹, ¹Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA, ²Harbor-UCLA and Los Angeles Biomedical Institute, Torrance, CA
Background/Purpose: Biologic disease-modifying antirheumatic drugs (bDMARDs) may decrease cardiovascular events (CVE) in Rheumatoid arthritis (RA). We here evaluated whether bDMARDs reduce long-term CVE risk in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].